Clinical trials
Cytomegalovirus clinical trials
Below are recruiting cytomegalovirus clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06793124Recruiting
Comparing tests for CMV in bowel disease patients
This trial compares different diagnostic tests to find the best way to detect cytomegalovirus (CMV) organ disease in people with inflammatory bowel disease (IBD) whose symptoms get worse and need hospital care. The goal is to improve diagnosis and treatment for this complication.
Bologna, BolognaAges 18 years+ - NCT06916195Recruiting
CMV virus reactivation in kids after stem cell transplant
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
GenovaAges birth–18 years - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05446571RecruitingPhase 3
Letermovir in pregnancy versus valaciclovir for fetal CMV
This trial tests whether letermovir can treat a baby’s early (first-trimester) congenital CMV infection in pregnancy, compared with the standard drug valaciclovir. The goal is to reduce serious effects from CMV while monitoring safety and pregnancy outcomes.
ParisAges 18 years+ - NCT05432778RecruitingPhase 2
Letermovir to prevent CMV in new heart transplant patients
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
LjubljanaAges 18–70 - NCT04056533RecruitingPhase 2
Preventing CMV after a haploidentical stem cell transplant
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
SantanderAges 18–80 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Birmingham, AlabamaAges 18 years+ - NCT07199465RecruitingPhase 1
Letermovir for children after a kidney transplant
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
Birmingham, AlabamaAges Up to 17 years - NCT05708508RecruitingPhase 3
Immune-guided vs universal medicine to prevent CMV after kidney transplant
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
RouenAges 18–75 - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT06574789RecruitingPhase 2
Personalized ganciclovir dosing for CMV in children with weak immune systems
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
Sydney, New South WalesAges 1 month–18 years - NCT06520605Recruiting
CMV reactivation in ICU patients on ventilators for a week or more
This study looks at whether a common virus called cytomegalovirus (CMV) becomes active again in ICU patients who need a breathing machine for a week or more. It may help doctors understand who is at risk and how to better care for them.
Lucknow, Uttar PradeshAges 18–80 - NCT05708755RecruitingPhase 2
Monitoring immune response to CMV after lung transplant
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
New York, New YorkAges 18–99 - NCT06926894RecruitingPhase 1
A cell therapy for viral infections in children and young adults
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
New York, New YorkAges 3 months–26 years - NCT07709013RecruitingPhase 2
Leflunomide to stop CMV after stem cell transplant
This study tests whether the drug leflunomide can prevent CMV virus reactivation after a half-matched stem cell transplant. If you have already had a successful white blood cell recovery and no sign of CMV, this might help keep you safe from the virus.
Navi Mumbai, MaharashtraAges 18 years+ - NCT04439916Recruiting
Preventing CMV after lung transplant in special donor/recipient pairs
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Edmonton, AlbertaAges 18 years+ - NCT05183490RecruitingPhase 1
Cell therapy for repeated viral infections after transplant
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
New York, New YorkAges 18 years+ - NCT05626530RecruitingPhase 4
Letermovir to prevent CMV after transplant illness
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
Boston, MassachusettsAges 18–75 - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100 - NCT06066957RecruitingPhase 2
Oral letermovir to prevent CMV after heart or lung transplant
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06341543Recruiting
CMV blood test to guide treatment after organ transplant
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
Grenoble, MarylandAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+
Hear when a new Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cytomegalovirus?
- Yes. Clin2 currently lists 61 recruiting cytomegalovirus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cytomegalovirus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cytomegalovirus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.